8-K current report · filed Nov 13, 2026

Tvardi Therapeutics, Inc. (TVRD) 8-K Current Report: November 13, 2026

Item 2.02Item EX-99.1TVRD overview

Short answer

Tvardi Therapeutics, Inc. (TVRD) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal quarter results for period ended September 30, 2026 announced on November 13, 2026.

Tvardi Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal quarter results for period ended September 30, 2026 announced on November 13, 2026
  • Business highlights included alongside quarterly financial results
  • Exhibit 99.1 contains the detailed financial metrics and operating update

Item EX-99.1 · Exhibit EX-99.1

  • Q3 net loss $6.1M, or $(0.48) per share, versus $5.5M and $(0.59) year over year
  • R&D expense $4.5M, up from $3.6M, reflecting higher TTI-101 clinical costs
  • Cash and equivalents $22.3M versus $30.8M at December 31, 2025, with runway into Q3 2027
  • TTI-101 HCC topline data expected early Q1 2027, a key near-term clinical catalyst
  • TTI-109 UC trial initiation targeted for 2027, contingent on IND clearance and additional funding

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tvardi Therapeutics, Inc. 8-K filings

Get the next TVRD 8-K as it lands

Follow TVRD for push alerts, or ask the research agent what this filing means.